$12,171.84 consulting Payment -- Bristol-Myers Squibb to Dr. Mark Perez
Bristol-Myers Squibb paid Hepatologist Mark Perez $12,171.84 for consulting services.
This page provides a detailed analysis of a $12,171.84 consulting payment from Bristol-Myers Squibb to Dr. Mark Perez. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $12,171.84 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Bristol-Myers Squibb |
| Physician | Dr. Mark Perez |
| NPI Number | 1635197716 |
| Physician Specialty | Hepatology |
| Location | City, CO |
| Date of Payment | 2026-01-21 |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bristol-Myers Squibb made a $12.2K consulting payment to Mark Perez, a Hepatology specialist in City, CO. Bristol-Myers Squibb paid Dr. Mark Perez $12,171.84 for consulting services on January 21, 2026. The payment was categorized as a 'Consulting Fee' under the 'consulting' payment type. This payment represents a significant financial engagement between the pharma company and a Hepatology specialist.
Patient Guidance: What This Payment Means for You
If you are a patient, this record shows a payment made to your doctor for consulting services. Discuss any concerns about this with your doctor or a healthcare advocate. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For a Hepatology specialist, a payment of this amount for consulting services from a major pharmaceutical company is within a moderate range, though the specifics of the consulting work would determine its appropriateness.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- consulting-agreements
- hepatology
- drug-manufacturer-payments
- open-payments-data
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $12.2K payment for?
This was a consulting payment of $12.2K from Bristol-Myers Squibb to Mark Perez, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Mark Perez accept pharmaceutical money?
Yes, Mark Perez received this $12.2K payment from Bristol-Myers Squibb. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Mark Perez's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $12.2K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Hepatology?
To compare this payment against Hepatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hepatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Mark Perez's relationship with Bristol-Myers Squibb?
The payment amount is substantial for a single consulting engagement. This $12.2K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Hepatology?
The payment date is in the future, suggesting a planned or ongoing arrangement.
What should patients do after learning about this payment?
If you are a patient, this record shows a payment made to your doctor for consulting services. Discuss any concerns about this with your doctor or a healthcare advocate.
What else should I know about this consulting payment?
The specific nature of the consulting is detailed as 'Consulting Fee'.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.